Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

    Not Recruiting
  • End date
    Dec 30, 2022
  • participants needed
  • sponsor
    National Institute of Neurological Disorders and Stroke (NINDS)
Updated on 27 June 2022



COVID-19 can cause problems in different parts of the body. For most people, it causes fevers or trouble breathing. Some people might not recover all the way. Researchers want to see if 2 treatments can help with people who have recovered from COVID-19 but still have symptoms ( Long-Haul COVID ).


To learn if methylprednisolone (steroid) and human immunoglobulin (IVIG) will help with symptoms of Long-Haul COVID.


Adults ages 18 and older who had COVID-19 at least 6 weeks ago and have ongoing neurologic symptoms, such as dizziness, trouble walking, or problems with strength.


Participants will be screened with a medical record review.

Participants will have a physical exam and chest x-ray. They will complete questionnaires about their health and quality of life. They will have a spinal tap. They will give blood samples. They will discuss their symptoms with a neurologist and have an exam.

Participants will take memory and thinking tests using pen and paper. The tests will take 10-15 minutes to complete. They will also take a smell test with scratch-and-sniff books. It will take 5-10 minutes to complete.

Participants will lie on a table that tilts. Their blood pressure and heart rate will be monitored. Blood will be taken through an intravenous (IV) catheter.

Participants will receive either the steroid, IVIG, or saline by IV for 5 days. They will not know which treatment they get.

Participants may have an optional MRI of the brain and spine. They will receive a contrast agent by IV.

Participants will be on the study for up to 3 months. They may be asked to continue follow-up.


Study Description:

This study will evaluate the clinical and laboratory effects of immunotherapies in patients who recovered from acute mildmoderate COVID-19 infection but still have persistent neurologic symptoms. Despite clinical recovery from the acute infection, some individuals continue to experience ongoing symptoms, at times several months after recovery, and many of these symptoms are neurologic. Some features suggest that this is a post-infectious immune-mediated process, and anecdotally patients have responded well to immunotherapies. This study will evaluate the clinical and laboratory effects of the different proposed immunological interventions compared to placebo. It is hypothesized that these interventions could have positive clinical and laboratory effects on patients with persistent neurological symptoms.


Primary Objective: To compare the clinical effects of three study arms (intravenous immunoglobulin, intravenous steroids, or placebo) in participants with neurological post-acute sequalae of SARS-CoV-2 infection.

Secondary objective: To investigate laboratory effects of immunotherapies in patients with neurological post-acute sequalae of SARS-CoV-2 infection.


Primary endpoint:

Proportion of participants with a clinically meaningful change in Health Utilities Index Mark 3 (HUI3) 4 weeks after study intervention

Secondary endpoints:

  • Change in functional / patient-reported scales:
    1. WHO post COVID-19 functional scale
    2. Post-COVID-19 Functional Status (PCFS) scale (0-4).
    3. COVID-19 Yorkshire Rehabilitation Scale
    4. PROMIS Global Health score
    5. PROMIS Depression score
    6. PROMIS anxiety score
  • Change in clinical scales:
    1. Montreal Cognitive Assessment (MoCA)
    2. Brief tablet-based Neuropsychiatric evaluation
    3. Karnofsky Performance Status (KPS)
    4. University of Pennsylvania Smell Identification Test (UPSIT)
  • Autonomic testing - Change in the number and character of test results indicating autonomic nervous system dysfunctions as evidenced by abnormal physiological and neurochemical measures at rest or in responses to the Valsalva maneuver or head-up tilting.
  • Change in immunological markers:
    1. Cytokine levels
    2. Cell markers per flow cytometry

Condition Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis
Treatment Iv Methylprednisolone, IV normal saline, IV immunoglobulin, IV immunoglobulin
Clinical Study IdentifierNCT05350774
SponsorNational Institute of Neurological Disorders and Stroke (NINDS)
Last Modified on27 June 2022

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note